INTRODUCTION AND OBJECTIVES: Our team developed a novel treatment strategy of erectile dysfunction (ED). Stromal vascular fraction (SVF) is considered as promising cell-based product for treatment of wide variety of diseases without the need of cell expansion in vitro. SVF injection was proved to be safe in numerous preclinical and clinical trials. The aim of the present study was to evaluate safety and efficacy of intracavernosal injection of SVF (NCT02472431).
METHODS: The study included 12 men with vasculogenic ED (mean age 47 years, IIEF-5<21). Effect of pharmacological intervention (PDE-5) was insufficient. Aspirated adipose tissue was processed using Celution 800/CRS System (Cytori Therapeutics Inc). Obtained cells were resuspended in 2.0 mL of Hartmann's solution. SVF injection was performed on lateral surface of penis bilaterally proximally into the middle and distal parts of corpus cavernosum. Equal portions of ADRC suspension injected into both corpora cavernosa. Following methods: doppler ultrasonography combined with intracavernosal prostaglandin-E1 injection; EndoPAT; International Index of Erectile Function (IIEF-5); Sexual Encounter Profile (SEP); Erection Hardness Score (EHS).
RESULTS: Intracavernosal injections of SVF were well tolerated by all patients. Neither adverse events nor complications have been detected in the clinical study. 24 weeks after SVF injection systolic speed increased and reached on the left cavernous artery avg 36 (32 to 46) cm/s, the right cavernous artery avg 35 (30 to 49,5) cm/s; Resistance Index -the left cavernous artery 0,91 (0,83 to 0,97), the right cavernous artery 0,91 (0,85 to 0,97); IIEF-5-17 (13 to 20); EHS-3 (2 to 4); SEP-3 (2 to 4); EndoPAT -?ndothelial function was significantly improved 6 months after the procedure.
CONCLUSIONS: The study showed that effects of SVF injection contribute to recovery of erectile function. Results were confirmed by improvement of arterial blood flow and recovery of endothelial function. The proposed technique is safe and effective therefore it may be recommended as alternative treatment method of ED. Patent granted RU2622757. Now we are planning to start multicenter phase 2b study.
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PD33-08 SINGLE-CELL TRANSCRIPTOME ANALYSIS OF HUMAN SPERMATOGONIAL STEM CELLS
Hye-Won Song*, Tung-Chin Hsieh, La Jolla, CA; Sue Hammoud, Ann Arbor, MI; Miles Wilkinson, La Jolla, CA INTRODUCTION AND OBJECTIVES: e 2000 prepubertal boys in the U.S. become sterile every year as a result of gonadotoxic treatments for cancer. An approach to restore the fertility is spermatogonial stem cell (SSC) therapy. To achieve this, it is critical to identify human SSCs markers. Here, we identify a plethora of candidate SSC markers using single-cell RNA sequencing (SC-RNAseq).
METHODS: Adult human testicular biopsies were obtained from fertile donors. Neonatal testes were obtained from human babies who died from conditions unrelated to the testis. Testicular cells were dissociated and enriched for SSCs by magnetic activated cell sorting for the spermatogonia marker integrin-a6 (ITGA6). Both total and ITGA6þ testicular cells were analyzed by SC-RNAseq using the 10X Genomics platform. Cell subsets were defined using the t-Distributed Stochastic Neighbor Embedding (tSNE) algorithm.
RESULTS: Through transcriptomes analysis of individual adult testicular cells, we defined related cell types (cell clusters). Fig. 1A shows several cell clusters, including spermatogonia (SPG) subsets.
One of these SPG subsets was marked by several putative SSC markers defined by the field, including UTF1 and TCF3 (Figs. 1B and  C) , strongly suggesting that this subset is enriched for SSCs. As an independent means to identify SSCs, we compared adult SPG with neonatal prospermatogonia (ProSG), the precursor cells that give rise to SSCs. This analysis confirmed the identity of the adult SSC subset, as it clustered immediately adjacent to ProSG (Figs. 1D and E) . We identified several genes selectively expressed in this SSC subset, many of which are new candidate SSC markers. Unexpectedly, we also identified adult SPG that clustered precisely together with neonatal ProSG (Figs. 1D and E) . This cell subset is preferentially labeled by the stem cell marker OCT4 (Fig. 1F) and largely lacks proliferation gene expression, leading us to propose it is composed of quiescent reserve stem cells.
CONCLUSIONS: Using single-cell transcriptome analysis, we defined an adult SSC subset with characteristics of SSCs, including a close relationship with neonatal ProSG, the precursors of SSCs. Unexpectedly, we also identified an adult ProSG-like subset with characteristics of reserve stem cells. This ProSG-like subset may be the source of seminomas given that they are thought to arise from ProSG. To maintain these cellular characteristics, the regulation of genome transcription is mandatory, although the basis of this mechanism remains unknown. Recently, small mRNA, called microRNA (miRNA), consisting of 18e25 nucleotide bases have been recognized as key transcription regulators. The effect involves more than one-third of all transcription regulation. We hypothesized that miRNAs function as one of the key SSC regulators and are likely associated with SSC differentiation and thus aimed to find the miRNAs expressing in SSCs and its target mRNAs. Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 THE JOURNAL OF UROLOGY â e653
